Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Darifenacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 0.98 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 1/20 | 0.98 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | HRH2 | P25021 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darifenacin SCHEMBL113331 | 0.99 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL56574 | 0.99 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL2774455 | 0.99 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL31257801 | 0.99 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL1318587 | 0.98 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL138745 | 0.98 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL1023445 | 0.98 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL3662174 | 0.98 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL5085916 | 0.98 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL453486 | 0.98 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110144354-A1 | Process for Preparation of Darifenacin and Intermediates Used in the Process | Watson Pharma Private Limited (IN) | 2011-06-16 | — | — | US | claimed |
| WO-2010032225-A2 | PROCESS FOR PREPARATION OF DARIFENACIN AND INTERMEDIATES USED IN THE PROCESS | Watson Pharma Private Limited (IN) | 2010-03-25 | — | — | WO | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2008126106-A2 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF INTERMEDIATES OF DARIFENACIN, DARIFENACIN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | SATYANARAYANA REDDY MANNE (IN) | 2008-10-23 | — | — | WO | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| EP-1915992-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | Pharmacia Corporation (US) | 2008-04-30 | — | — | EP | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| WO-2007072503-A2 | COMBINATIONS FOR MANAGING INFLAMMATION AND ASSOCIATED DISORDERS | PANACEA BIOTEC LTD. (IN) | 2007-06-28 | — | — | WO | claimed |
| CN-1633283-A | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence | PHARMACIA CORP (US) | 2005-06-29 | — | — | CN | claimed |
| EP-1476146-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | Pharmacia Corporation (US) | 2004-11-17 | — | — | EP | claimed |
| US-20030191172-A1 | Method of using cyclooxygenase inhibitors and antimuscarinic agents | VERSI EBRAHIM (US) | 2003-10-09 | — | — | US | claimed |
| WO-2003070233-A1 | USE OF CYCLOOXYGENASE INHIBITORS AND ANTIMUSCARINIC AGENTS FOR THE TREATMENT OF INCONTINENCE | PHARMACIA CORPORATION (US) | 2003-08-28 | — | — | WO | claimed |
| US-20240123168-A1 | PRODUCT DELIVERY DEVICES AND METHODS | MUSTAPHA JIHAD A (US) | 2024-04-18 | — | — | US | disclosed |
| CN-117279681-A | Product delivery device and method | 呼吸解决方案股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-4255541-A1 | PRODUCT DELIVERY DEVICES AND METHODS | Breathe Restore, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-116507327-A | Chewable formulations | 礼蓝动物保健有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2007072503-A2 | COMBINATIONS FOR MANAGING INFLAMMATION AND ASSOCIATED DISORDERS | PANACEA BIOTEC LTD. (IN) | 2007-06-28 | — | — | WO | disclosed |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | MICHEL MARTIN C | 2007-04-05 | — | — | US | disclosed |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | US | disclosed |
| CN-1633283-A | Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence | PHARMACIA CORP (US) | 2005-06-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | ADRB3, ADRB2, ADRB1 | CHRM3 20/4885CHRM2 93/4885CHRM5 105/4885 |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | ADRB3, ADRB2, ADRB1 | CHRM3 19/4885CHRM2 45/4885CHRM5 49/4885 |
| US-20110144354-A1 | Process for Preparation of Darifenacin and Intermediates Used in the Process | OPRL1, OPRD1, OPRK1 | CHRM3 19/4885CHRM2 43/4885CHRM5 34/4885 |
| US-20030191172-A1 | Method of using cyclooxygenase inhibitors and antimuscarinic agents | PTGS2, PTGES2, PTGS1 | CHRM3 10/4885CHRM2 7/4885CHRM5 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.